| Literature DB >> 21272313 |
Ana Karina R Abadio1, Erika S Kioshima, Marcus M Teixeira, Natalia F Martins, Bernard Maigret, Maria Sueli S Felipe.
Abstract
BACKGROUND: The prevalence of invasive fungal infections (IFIs) has increased steadily worldwide in the last few decades. Particularly, there has been a global rise in the number of infections among immunosuppressed people. These patients present severe clinical forms of the infections, which are commonly fatal, and they are more susceptible to opportunistic fungal infections than non-immunocompromised people. IFIs have historically been associated with high morbidity and mortality, partly because of the limitations of available antifungal therapies, including side effects, toxicities, drug interactions and antifungal resistance. Thus, the search for alternative therapies and/or the development of more specific drugs is a challenge that needs to be met. Genomics has created new ways of examining genes, which open new strategies for drug development and control of human diseases.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21272313 PMCID: PMC3042012 DOI: 10.1186/1471-2164-12-75
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Potential target genes selected for new antifungal drug development
| Gene | Biological process | Cytolocalization | PDB template | Organism | PDB sequence identidy (%) | |
|---|---|---|---|---|---|---|
| Cell redox homeostasis | Cytoplasm | 3e-115 | 65 | |||
| 1e-94 | 57 | |||||
| Cellular metabolism | Golgi and membrane | * | * | * | * | |
| Ribosome biogenesis | Nucleolus | 7e-42 | 30 | |||
| Cell wall biogenesis/degradation | Membrane | * | * | * | * | |
| Protein transport | Mitochondrion membrane | 0.8 | 34 | |||
| Cell wall biogenesis/degradation | Golgi apparatus Membrane | 6e-4 | 32 | |||
| Cell wall organization/biogenesis | Membrane | 0.3 | 32 | |||
| Protein mannosilation | Golgi membrane | 6e-96 | 50 | |||
| Ergosterol biosynthesis | Endoplasmatic reticulum membrane | 5e-18 | 32 | |||
| pH-response regulator | Cytoplasm | 3,9 | 38 |
* Structure absent in PDB (http://www.rcsb.org/pdb/home/home.do)
Figure 1Phylogenetic analysis between human pathogenic fungi performed by Bayesian analysis. Phylogenetic trees generated from Bayesian analysis of the genes trr1 (a), rim8 (b), kre2 (c) and erg6 (d). The length of the vertical lines linking one protein is proportional to the estimated distance between their sequences. The posterior probability values were added to the phylogenetic branches. Af: Aspergillus fumigatus, Bd: Blastomyces dermatitidis, Ca: Candida albicans, Ci: Coccidioides immitis, Cn: Cryptococcus neoformans, Hc: Histoplasma capsulatum, Pl: Paracoccidioides lutzii, Pb3: P. brasiliensis isolate 3, Pb18: P. brasiliensis isolate 18.
Figure 2The predicted tridimensional structure of TRR1 and KRE2 proteins obtained by homology modeling. The structures of TRR1 (a) and KRE2 (b) proteins. The α-helix is represented by the color red, the β-sheet is represented by yellow and loops are represented by green. (a - left panel) The KRE2 active site presents the conserved residues His292, His357, Asp330 and Glu298. (Mutation of these residues abolished the protein activity in C. albicans.) Additional residues found in the KRE2 active site include Glu216, which interacts with the metal ion Mn2+ and creates the reactive nucleophylic center for the glycosyltransferase reaction, and Tyr189, which coordinates the donor and acceptor binding that allows the transfer of the mannose to the growing oligosaccharide. (b - right panel) The TRR1 protein is composed of two domains that comprise the binding sites of NADPH and FAD. The NADPH binding domain contains the active Cys145 and Cys148 residues. Other important residues of the TRR1 active site are Ala151, Val152, Pro153 and Ile154 that form a hydrophobic region in the NADPH binding domain.